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Background: Asthma is classified according to severity and inflammatory phenotype 
and is likely to be distinguished by specific microRNA (miRNA) expression profiles. 
Objective: We sought to associate miRNA expression in sputum supernatants with 
the inflammatory cell profile and disease severity in asthmatic patients. 
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Methods: We investigated miRNA expression in sputum supernatants of 10 healthy 
subjects, 17 patients with mild-to-moderate asthma, and 9 patients with severe 
asthma using high-throughput, stem-loop, reverse transcriptase quantitative real-time 
PCR miRNA expression profiling (screening cohort, n = 36). Differentially expressed 
miRNAs were validated in an independent cohort (n = 60; 10 healthy subjects and 50 
asthmatic patients). Cellular miRNA origin was examined by using in situ 
hybridization and reverse transcriptase quantitative real-time PCR. The functional 
role of miRNAs was assessed by using in silico analysis and in vitro transfecting 
miRNA mimics in human bronchial epithelial cells. Results: In 2 independent cohorts 
expression of miR-629-3p, miR-223-3p, and miR-142-3p was significantly 
upregulated in sputum of patients with severe asthma compared with that in healthy 
control subjects and was highest in patients with neutrophilic asthma. Expression of 
the 3 miRNAs was associated with sputum neutrophilia, and miR-223-3p and miR-
142-3p expression was associated also with airway obstruction (FEV1/forced vital 
capacity). Expression of miR-629-3p was localized in the bronchial epithelium, 
whereas miR-223-3p and miR-142-3p were expressed in neutrophils, monocytes, 
and macrophages. Transfecting human bronchial epithelial cells with miR-629-3p 
mimic induced epithelial IL-8 mRNA and protein expression. IL-1β and IL-8 protein 
levels were significantly increased in sputum of patients with severe asthma and 
were positively associated with sputum neutrophilia. Conclusions: Expression of miR-
223-3p, miR-142-3p, and miR-629-3p is increased in sputum of patients with severe 
asthma and is linked to neutrophilic airway inflammation, suggesting that these 
miRNAs contribute to this asthma inflammatory phenotype. (J Allergy Clin Immunol 
2016;137:1433-46.) 
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Asthma is a chronic inflammatory airway disease characterized by airway 
hyperresponsiveness and reversible airway obstruction resulting in recurrent 
episodes of wheezing, shortness of breath, chest tightness, and cough. Asthma can 
be categorized into different phenotypes depending on the inflammatory profile 
(eosinophilic, neutrophilic, mixed granulocytic, and paucigranu-locytic), presence of 
allergy (atopic vs nonatopic), and age of onset (childhood vs adult onset)1. This 
phenotyping has important therapeutic implications and can lead to more 
personalized medicine, in which identification of specific biomarkers or molecular 
mechanisms paves the way for specific (add-on) treatment. Such approaches can be 
especially relevant for patients with severe asthma, in whom current standard 
therapies do not offer sufficient benefit. 
Both genetic and epigenetic alterations contribute to altered immune responses 
within the lungs of asthmatic patients. MicroRNAs (miRNAs) are highly conserved 
small, single-stranded, noncoding RNA molecules that control gene expression by 
targeting mRNAs for degradation or translational repression.2 By targeting 
transcriptional activators or repressors, miRNAs can simultaneously regulate the 
expression of hundreds of genes, including other miRNAs. In this way miRNAs 
control various processes, such as cell proliferation, differentiation, and apoptosis. In 
patients with inflammatory conditions, miRNAs function in complex regulatory 
networks in which their expression can be controlled by either feed-forward or feed-
backward mechanisms.3 Although several studies addressing the role of specific 
miRNAs in asthmatic patients have been performed in mice, the number of studies in 
human airways, especially with regard to severe asthma, is very low.3 In lung biopsy 
specimens of patients with mild asthma, no significant differences in miRNA 
expression could be demonstrated compared with healthy subjects.4 In bronchial 
epithelial brushings of patients with mild-to-moderate asthma, changes in miRNA 
expression were reported, including downregulation of the miR-34/449 family, which 
could be mimicked by treatment with IL-13 and partly restored by corticosteroids.5 In 
another miRNA profiling study with bronchial brushings of asthmatic patients, 
bioinformatics analysis revealed that the predicted miRNA targets belonged to a 
proinflammatory molecular network, which was confirmed by gene expression 
measurements.6 Primary cell-culture studies on bronchial biopsy specimens of 
patients with severe asthma have revealed a role for miR-19a and miR-221 in 
epithelial cell and airway smooth muscle cell proliferation, respectively.7,8 A TH2 
cytokine-promoting role of miR-19a in patients with mild-to-moderate asthma was 
also demonstrated.9 However, to our knowledge, no study has linked miRNA 
expression in the airways of patients with severe asthma to inflammatory 
phenotypes. 
We have previously reported altered miRNA expression profiles in induced sputum 
supernatant of patients with chronic obstructive pulmonary disease. In the current 
study we performed miRNA gene expression analysis on induced sputum 
supernatants from 2 independent cohorts of well-characterized patients with mild-to-
moderate or severe asthma and associated miRNA expression with inflammatory 
phenotypes. In both the screening and validation cohorts, we demonstrate that 
expression of miR-629-3p, miR-223-3p, and miR-142-3p is increased in patients with 
severe asthma and is associated with sputum neutrophilia, suggesting that these 
miRNAs contribute to disease mechanisms in patients with neutrophilic asthma. 
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TABLE I. Demographic, functional, and inflammatory characteristics of the screening 
cohort according to disease severity 
Screening cohort Healthy 
subjects 
Patients with mild-to-moderate 
asthma 
Patients with severe 
asthma 
No. 10 17 9 
Demographic characteristics    
Age (y), median (IQR) 40 (28-55) 58 (51-66) 50 (46-63) 
Sex (M/F) 3/7 5/12 2/7 
BMI (kg/m
2
), mean ± SD 24.5 ± 3.5 27.1 ± 5.5 27.6 ± 6.5 
Atopy,* no. (%) 4 (40) 10 (59) 6 (67) 
Smoking status (nonsmoker/ex-
smoker)† 
8/2 13/4 4/5 
Functional characteristics and therapy  
FEV1 (%), mean ± SD 98.2 ± 17.8 97.7 ± 13.8 53.8 ± 12.3||# 
FEV1/FVC ratio (%), mean ± SD 80.1 ± 6.3 74.1 ± 5.3 § 61.1 ± 9.8||# 
Reversibility (%), mean ± SD — 7.1 ± 7.6 17.4 ± 28.1 
ACQ score, median (IQR) ND 0.7 (0.3-1.1) 2.8 (1.9-3.9)# 
FENO (ppb), median (IQR) 18.8 (15.9-22.8) 32.3 (23.8-50.0) 22.5 (16.5-72.9) 
ICS therapy (yes/no) 0/10 8/9 § 9/0||¶ 
ICS dose, median (IQR) 0 0 (0-800)§ 2000 (1600-4000)||# 
Sputum characteristics    
Inflammatory phenotype ‡ : 
eosinophilic/ 
neutrophilic/paucigranulocytic 
0/0/10 11/4/2|| 5/4/0|| 
Macrophages (%) 62.7 (34.1-82.6) 21.2 (16.6-57.8) 12.0 (3.5-20.3)|| 
Neutrophils (%) 22.5 (1.3-62.8) 39.0 (15.5-71.0) 72.0 (43.6-93.8) 
Eosinophils (%) 0.0 (0.0-0.0) 7.8 (0-26.9)§ 8.5 (1.2-19.7)§ 
Data are expressed as distributions (yes/no), means ± SDs, or medians with IQRs. Comparisons were 
done with Pearson χ
2
   tests or the Kruskal-Wallis test, followed by the 
Mann-Whitney U test with the Bonferroni correction. 
ACQ, Asthma Control Questionnaire; F, female; FENO, fraction of exhaled nitric oxide; IQR, 
interquartile range; M, male; ND, not determined. 
* Atopy is defined as positive test results for at least 1 specific IgE to common aeroallergens (see the 
Methods section for more information). 
†Ex-smoker is defined as not smoking since at least 6 months. 
‡Sputum eosinophilic inflammation, ≥3% eosinophils and <76% neutrophils; neutrophilic inflammation, 
≥76% neutrophils and <3% eosinophils; paucigranulocytic inflammation, 
eosinophils ≤3% and neutrophils ≤76% neutrophils. 
§P < .05 versus healthy subjects. 
||P < .001 versus healthy subjects. 
¶ P < .05 versus patients with mild-to-moderate asthma. 
#P < .001 versus patients with mild-to-moderate asthma. 
 
METHODS 
Subject characteristics and study design of the screening and validation 
cohorts 
Two independent study populations were enrolled at the asthma clinic in CHU Liege 
(Belgium). Healthy subjects were recruited at the hospital and University of Liege, 
Belgium. All subjects from both cohorts were nonsmokers (never smokers or ex-
smokers who quit smoking for at least 6 months). 
The screening cohort consisted of healthy subjects (n = 10), patients with mild-to-
moderate asthma (n = 17), and patients with severe asthma (n = 9). The validation 
cohort consisted of healthy subjects (n = 10), patients with mild-to-moderate asthma 
(n = 29), and patients with severe asthma (n = 21). Tables I and II provide an 
overview of the demographic, functional, and treatment characteristics of the 36 
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subjects from the screening cohort and 60 subjects from the validation cohort, 
according to disease severity and inflammatory phenotype, respectively. See this 
article's Online Repository at www.jacionline.org for additional details. 
Asthma severity was evaluated by a respiratory physician based on a combination of 
symptoms, lung function, and amount of medication to achieve control (Global 
Initiative for Asthma [GINA]11 and European Respiratory Society/American Thoracic 
Society guidelines12). Severe asthma required GINA treatment steps 4 to 5 (≥1000 
µg of beclomethasone/d and long-acting β2-agonist), to prevent it to become 
uncontrolled or remained uncontrolled despite this therapy (uncontrolled asthma 
defined as poor symptom control [Asthma Control Questionnaire score >1.5] and/or 
reduced lung function [FEV1 <80% of predicted value]). Patients with mild-to-
moderate asthma were defined as asthmatic patients treated with a low dose of 
inhaled corticosteroid (ICS; <1000 µg of beclomethasone/d) or did not yet receive 
treatment and had an FEV1 of 80% or greater of predicted value. 
Subjects were considered atopic if they had positive test results for at least 1 specific 
IgE (>0.35 kU/L; Phadia, Groot-Bijgaarden, Belgium) toward common aeroallergens 
(cat, dog, house dust mite, grass pollen, tree pollen, and a mixture of molds), had a 
positive skin prick test response, or both. 
The study was approved by the local ethics committee, University of Liege, Belgium, 
(reference 2005/181; conforming to the declaration of Helsinki). 
 
Sputum induction 
Sputum was induced and processed, as described previously.13,14 See the Methods 
section in this article's Online Repository at www.jacionline.org for more details. 
Whole sputum was weighted, and 3 volumes of PBS were added. After 
homogenizing by means of manual agitation for 30 seconds and centrifugation (800g) 
for 10 minutes at 4°C, the cell pellet and supernatant were separated. Sputum cell 
differentials were determined by counting 500 cells on cytospin samples stained with 
Rapi-Diff II stain (Atomic Scientific, Manchester, United Kingdom) and used to define 
asthma inflammatory phenotypes. Eosinophilic asthma was defined as 3% or greater 
sputum eosinophils and less than 76% sputum neutrophils, neutrophilic asthma was 
defined as 76% or greater neutrophils and less than 3% eosinophils, and 
paucigranulocytic asthma was defined as less than 3% eosinophils and less than 
76% neutrophils.15 Patients with mixed granulocytic asthma (≥76% neutrophils and 
≥3% eosinophils) were excluded. 
 
miRNA detection in sputum supernatants 
Total RNA from cell-free sputum supernatants (150 µL) was extracted by using 
miRNeasy Micro Kit without carrier RNA, according to the manufacturer's guidelines 
(Qiagen, Hilden, Germany). miRNA profiling on 80 ng of RNA was performed at 
Biogazelle (Zwijnaarde, Belgium) by using high-throughput, stem-loop RT 
quantitative real-time PCR (qPCR) miRNA expression profiling. See the Methods 
section in this article's Online Repository for more details and see the Online 
Repository for Cq values. The detection cutoff was put at a Cq value of 32. Data 
normalization was performed in qbase + software (Biogazelle, 
http://www.qbaseplus.com) by using the modified global mean normalization 
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procedure. Normalized expression data (calibrated normalized relative quantities) are 
logio-transformed. 
In the validation study expression of miR-629-3p, miR-223-3p, and miR-142-3p was 
quantified with specific TaqMan Micro Assays (Life Technologies, Grand Island, NY) 
by using a custom RT and preamplification pool (12-cyle PCR, according to the 
manufacturer's guidelines). See the Methods section in this article's Online 
Repository for more details. Data were normalized in qbase + by using 2 stably 
expressed miRNAs (miR-20a and miR-30b) identified in the screening cohort. The 
normalized expression data are logio-transformed before data analysis. 
 
TABLE II. Demographic, functional, and inflammatory characteristics of the validation 
cohort population according to inflammatory phenotype 
Validation cohort Healthy subjects Patients with eosinophilic 
asthma‡ 
Patients with neutrophilic 
asthma 
No. 10 29 21 
Demographic characteristics    
Age (y), median (IQR) 53 (31-58) 52 (41-64) 61 (49-69) 
Sex (M/F) 6/4 12/17 5/16 
BMI (kg/m
2
), mean ± SD 23.9 ± 3.0 26.6 ± 4.5 25.6 ± 4.3 
Atopy,* no. (%) 3 (30) 19 (66) 10 (48) 
Smoking status (nonsmoker/ex-
smoker)† 
7/3 19/10 12/9 
Functional characteristics and therapy 
Ratio mild/severe asthma — 18/11 11/10 
FEV1 (%), mean ± SD 107.3 ± 12.8 82.3 ± 19.6 || 78.7 ± 22.8§ 
FEV1/FVC ratio (%), mean ± SD 80 ± 6.1 69.9 ± 8.2§ 68.5 ± 11.0§ 
Reversibility (%), mean ± SD 0.0 (-3.0 to 5.0) 10.8 ± 10.4§ 12.5 ± 15.6 
ACQ score, median (IQR) ND 1.6 (1.2-2.4) 2.1 (1.4-2.8) 
FENO (ppb), median (IQR) 24.0 (13.0-27.5) 34.5 (16.0-58.2) 19.9 (15.0-37) 
ICS therapy (yes/no) 0/10 17/12§ 14/7|| 
ICS dose, median (IQR) 0 400 (0-2000)§ 600 (0-2000)§ 
Sputum characteristics    
Macrophages (%) 44.2 (32.6-64.8) 28.6 (22.6-38.8)§ 10.0 (4.0-15.0)||¶ 
Neutrophils (%) 42.8 (19.9-63.1) 35.0 (19.2-51.0) 85.0 (79.6-92.5)||¶ 
Eosinophils (%) 0.0 (0.0-0.4) 21.0 (7.7-29.0)|| 0.2 (0.0-0.8)1 
Data are expressed as distributions (yes/no), means ± SDs, or medians with IQRs. Comparisons were 
done with Pearson χ
2
 tests or the Kruskal-Wallis test, followed by the 
Mann-Whitney U test plus Bonferroni correction. 
ACQ, Asthma Control Questionnaire; F, female; FENO, fraction of exhaled nitric oxide; IQR, 
interquartile range; M, male; ND, not determined. 
* Atopy is defined as positive test results for at least 1 specific IgE to common aeroallergens (see the 
Methods section for more information). 
†Ex-smoker is defined as not smoking since at least 6 months. 
‡Sputum eosinophilic inflammation, ≥3% eosinophils and <76% neutrophils; neutrophilic inflammation, 
≥76% neutrophils and <3% eosinophils. 
§P < .05 versus healthy subjects. 
|| P <.001 versus healthy subjects. 
¶P < .001 versus patients with eosinophilic asthma (see the Methods section for the full table). 
 
Protein measurements 
Levels of human IL-1β, IL-6, IL-8, and IL-5 protein in sputum supernatants were 
measured with the BD Cytometric Bead Array (Becton Dickinson, San Jose, Calif), a 
bead-based immunoassay. Detection limits for the proteins were 2.3 pg/mL for IL-1β, 
1.2 pg/mL for IL-8, 1.6 pg/mL for IL-6, and 1.1 pg/mL for IL-5. Measurements were 
performed on a FACSCalibur flow cytometer, according to the Cytometric Bead Array 
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instruction manual. 
Protein levels of IL-8 were measured in supernatants of human bronchial epithelial 
cells (HBECs) with a human CXCL8/IL-8 DuoSet ELISA (R&D Systems, Minneapolis, 
Minn). 
 
In situ hybridization for miRNAs 
In situ hybridization was performed on bronchial biopsy specimens from patients with 
severe asthma and control subjects (obtained from Professor Ricciardolo; approved 
by the local ethic committee of the San Luigi Hospital, Turin, Italy: protocol 1759, 
2008; conforming to the declaration of Helsinki); each subject provided written 
informed consent. Asthma diagnosis and severity were based on GINA and 
European Respiratory Society/American Thoracic Society guidelines.11,12 
Bronchoscopy was performed with a flexible fiberoptic bronchoscope (Pentax FB-
18P; Asahi Optical, Tokyo, Japan), and bronchial (segmental/lobar airways) biopsy 
specimens were gently extracted, as previously described.18 
More details on in situ hybridization are provided in the Methods section in this 
article's Online Repository. Fig E1 in this article's Online Repository at 
www.jacionline.org shows in situ hybridization with scrambled negative controls. 
For more details on neutrophil elastase staining, see the Methods section in this 
article's Online Repository. 
 
Flow cytometry and miRNA analysis on sorted sputum cells 
Sputum cells (10,000/cell type) were sorted on a FACSAria II (BD) to greater than 
92% purity and captured in QIAzol, followed by RNA extraction, cDNA synthesis, and 
RT-PCR with Qiagen reagents. Neutrophils were defined as CD45+CD14-CD16+, 
monocytes as CD45+CD14- side scatter (SSC)low, and macrophages as CD45+CD14-
SSChigh based on the method of Brooks et al.19 More details are presented in the 
Methods section in this article's Online Repository, including the gating strategy. 
For more information on in silico analysis into the functional role of miRNAs, see the 
Methods section in this article's Online Repository. 
 
Transfection of HBECs with miRNA mimics 
Normal HBECs (CC-2540; Lonza, Basel, Switzerland) were cultured in BEGM 
medium (CC-3170, Lonza), according to the manufacturer's guidelines. At passage 2, 
150,000 cells were transfected with mirVana 30 nmol/L miRNA mimics and controls 
(Ambion, Life Technologies) in 6-well plates by using lipofectamine (RNAiMAX; 
Invitrogen, Carlsbad, Calif; n = 4 for each condition). Forty-eight hours after 
transfection, culture supernatants was collected, and cells were lysed in QIAzol, 
followed by RNA extraction and RT-PCR. mRNA gene expression was normalized to 
3 reference genes (RPL13A, HPRT, and GAPDH) with qbase+ software (Biogazelle, 
http://www.qbaseplus.com), followed by data analysis. More details are presented in 
the Methods section in this article's Online Repository. 
 
Statistical analysis 
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For continuous variables, results are expressed as means ± SDs; medians and 
interquartile ranges were used for skewed distributions (verified by distribution graph 
and skewness factor >1). For categorical variables, the number or percentage 
distribution of each category within the groups is shown. Comparisons between 
groups were performed either with nonparametric tests (Kruskal-Wallis, followed by 
the Mann-Whitney U test for pairwise comparisons or Fisher exact tests) or 
parametric tests (ANOVA followed by least significant difference tests, in case of 
normal distribution and similar variance among groups). P values of less than .05 
were considered significant. 
The association between differentially expressed miRNAs and clinical parameters, 
inflammatory cell counts, or cytokine levels was determined with the Spearman rank 
correlation coefficient. Multiple linear regression analysis was performed modeling all 
predictive factors (percentage neutrophils, FEV1/forced vital capacity [FVC], pack 
years, ICSs, age, atopy, sex, and body mass index [BMI]) in a first step, followed by 
stepwise selection of most contributing factors. Statistical analysis was performed 
with SPSS statistics software (Version 21; SPSS, Chicago, I11). 
Only those miRNAs that were detectable (Cq <32) in at least 80% of the samples of 
one of the groups were further analyzed to investigate differential miRNA expression 
between the groups of the screening cohort. The miRNAs with undetectable 
expression levels were imputed by subtracting one log2 value from the minimum 
expression of this miRNA across samples of the cohort. Differential miRNA 
expression between 2 test groups was calculated in the data analysis software 
R3.1.2. with the limma package. An adjusted P value of less than .05 (false discovery 
















FIG 1. miRNA profiling in the screening cohort. A and C, Volcano plots of the -log10-adjusted P values 
versus the log10 fold changes in miRNA expression between groups. The horizontal line represents the 
significance level of the false discovery rate-adjusted P values (P < .05 was considered significant), 
indicating all miRNAs above this line are differentially expressed. A log10 fold change of 0.3 indicates a 
2-fold increase in miRNA expression. Fig 1, A, Healthy subjects (n = 10) compared with patients with 
severe asthma (n = 9); Fig 1, C, patients with neutrophilic asthma (n = 8) compared with healthy 
subjects (n = 10). B and D, Hierarchic clustering of the top 20 most differentially expressed miRNAs in 
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sputum supernatants. Samples are based on asthma severity (Fig 1, B) orthe inflammatory phenotype 
(Fig 1, D). The heat map was built by using Manhattan distance and the Ward method. Red indicates 
an expression level greater than the mean across all subjects, and blue indicates an expression level 










FIG 2. Validation cohort: normalized miRNA expression levels (log10-based) determined by using qRT-
PCR. A, Expression of miRNAs according to asthma severity. The mild asthma category includes 
patients with mild-to-moderate asthma. B, Expression of miRNA according to inflammatory phenotype 
(eosinophilic asthma, ≥3% eosinophils and <76% neutrophils in sputum; neutrophilic asthma, ≥76% 
neutrophils and <3% eosinophils in sputum). *P< .05, **P< .01, and ***P< .001. 
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Characteristics of the screening cohort 
Table I shows demographic, functional, and sputum characteristics of the 36 subjects 
(more details are provided in Table E1 in this article's Online Repository at 
www.jacionline.org). The screening cohort consisted of 10 healthy subjects, 17 
patients with mild-to-moderate asthma (ICS dose <1000 µg of beclomethasone/d or 
no ICS and FEV1≥80% of predicted value), and 9 patients with severe asthma (ICS 
dose ≥1000 µg of beclomethasone/d plus long-acting β2-agonist and FEV1 <80% of 
predicted value). There were no significant differences in age, sex, BMI, atopy, 
smoking status, and pack years among the 3 groups. Patients with severe asthma 
had significantly lower FEV1, FEV1/FVC ratio, and higher Asthma Control 
Questionnaire scores compared with healthy subjects and patients with mild-to-
moderate asthma. Within the mild-to-moderate asthma group, 52.9% were ICS naive, 
and 47.1% were treated with low-to-moderate doses of ICSs. Based on differential 
cell counts in induced sputum, the inflammatory phenotype of patients with asthma 
was eosinophilic (16/26), neutrophilic (8/26), or paucigranulocytic (2/26). Compared 
with healthy subjects, the percentage of eosinophils was higher in both asthmatic 
groups, whereas the percentage of sputum neutrophils tended to be higher in 
patients with severe asthma (P = .066). 
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Differential expression analysis of miRNAs in healthy control subjects 
compared with patients with (severe) asthma in the screening cohort. 
Expression analysis was performed for 755 miRNAs, followed by differential 
expression analysis for 171 miRNAs that were detectable in at least 80% of the 
sputum samples from 1 group (healthy subjects, patients with mild-to-moderate 
asthma, or patients with severe asthma). Comparison of miRNA expression in 
healthy subjects versus patients with severe asthma revealed 3 miRNAs with 
expression that was significantly increased in patients with severe asthma: miR-629-
3p, miR-223-3p, and miR-142-3p (false discovery rate, <0.05; Fig 1, A and B). 
Comparison of patients with mild-to-moderate asthma with patients with severe 
asthma or comparison of healthy subjects with patients with mild-to-moderate asthma 
showed no differentially expressed miRNAs (see Table E2 in this article's Online 
Repository at www.jacionline.org). 
 
Expression of miRNAs in healthy control subjects versus patients with 
eosinophilic or neutrophilic asthma in the screening cohort 
Considering the clinical relevance of inflammatory phenotypes in asthmatic patients, 
we investigated miRNA expression profiles according to the asthma inflammatory 
phenotype. The screening population consisted of 10 healthy control subjects, 16 
patients with eosinophilic asthma, and 8 patients with neutrophilic asthma. See Table 
E3 and the Results section in this article's Online Repository at www.jacionline.org 
for details on demographic, functional, and sputum characteristics of the screening 
cohort based on inflammatory phenotype. 
Expression of miR-629-3p, miR-223-3p, and miR-142-3p in sputum tended to 
increase in patients with neutrophilic asthma compared with that in healthy subjects 
(false discovery rate: 0.052, 0.065, and 0.065, respectively; Fig 1, C and D and 
Tables E4 and E5 for raw Cq values in this article's Online Repository at 
www.jacionline.org). Comparing patients with eosinophilic asthma with healthy 
subjects and patients with eosinophilic asthma with patients with neutrophilic asthma 









FIG 3. Validation cohort. A-C, Spearman correlation between the percentage of sputum neutrophils 
and expression of miR-629-3p (Fig 3, A), miR-223-3p (Fig 3, B), and miR-142-3p (Fig 3, C). D-F, 
Spearman correlation between the percentage of sputum macrophages and expression of miR-629-3p 
(Fig 3, D), miR-223-3p (Fig 3, E), and miR-142-3p (Fig 3, F). G-l, Spearman correlation between 
miRNA expression in sputum supernatants. Fig 3, A, miR-223-3p and miR-142-3p; Fig 3, B, miR-223-
3p and miR-629-3p; and Fig 3, C, miR-142-3p and miR-629-3p. 
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Characteristics of the validation cohort 
Because the data from the screening cohort suggested that miR-629-3p, miR-223-3p, 
and miR-142-3p expression was not only increased in patients with severe asthma 
but also linked to neutrophilic asthma, we selected an independent validation cohort 
of 60 subjects, including 10 healthy control subjects and 50 asthmatic patients (29 
patients with mild-to-moderate and 21 patients with severe asthma) with either an 
eosinophilic or neutrophilic phenotype. Characteristics of the validation cohort based 
on disease severity or inflammatory phenotype are summarized in Table II (more 
details are provided in Tables E6 and E7 in this article's Online Repository at 
www.jacionline.org). There were no significant differences in sex, atopy, smoking 
status, and pack years when groups were compared according to either disease 
severity or inflammatory profile. Patients with severe asthma had significantly lower 
lung function and significantly higher Asthma Control Questionnaire scores compared 
with patients with mild-to-moderate asthma and healthy subjects (see Table E6). 
Within the asthmatic groups, 29 of 50 patients had an eosinophilic (≥3% sputum 
eosinophils and <76% neutrophils) and 21 of 50 had a neutrophilic phenotype (≥76% 
sputum neutrophils and <3% eosinophils). 
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Confirmation of miR-629-3p, miR-223-3p, and miR-142-3p expression in 
patients with severe asthma in the independent validation cohort 
Validation of the miRNA expression of the top 3 differentially expressed miRNAs 
(miR-629-3p, miR-223-3p, and miR-142-3p) was performed in the independent 
validation cohort by using RT-qPCR. Similar to the screening cohort, miR-629-3p, 
miR-223-3p, and miR142-3p expression was significantly increased in patients with 
severe asthma versus healthy subjects. In addition, levels were significantly higher in 
patients with severe asthma compared with those in patients with mild-to-moderate 
asthma (Fig 2, A). 
In both cohorts expression levels of miR-223-3p and miR-142-3p were negatively 
associated with the FEV1/FVC ratio and FEV1 (see Table E8 in this article's Online 
Repository at www.jacionline.org). 
 
Increased miR-629-3p, miR-223-3p, and miR-142-3p expression is associated 
with neutrophilic asthma. 
Expression levels of the 3 identified miRNAs in the validation cohort were also 
compared based on inflammatory phenotype. Expression of miR-629-3p, miR-223-
3p, and miR-142-3p was significantly increased in patients with neutrophilic asthma 
compared with that in patients with eosinophilic asthma and healthy control subjects 
(Fig 2, B). 
Multiple regression analysis with age, BMI, atopy, sex, FEV1/FVC ratio, ICS use, 
neutrophil percentage, and pack years as predictor variables was followed by 
stepwise multiple linear regression. 
We further examined whether differences in miRNA expression could be detected 
within the mild-to-moderate or severe asthma groups with regard to inflammatory 
phenotype. For the 3 miRNAs, the expression was significantly increased in patients 
with mild-to-moderate neutrophilic asthma compared with those with mild-to-
moderate eosinophilic asthma and healthy control subjects. In patients with severe 
asthma, miR-223-3p and miR-142-3p expression was significantly increased in 
patients with neutrophilic asthma compared with those with eosinophilic asthma, 
whereas miR-629-3p expression tended to increase (see Fig E2 in this article's 
Online Repository at www.jacionline.org). 
Correlation analysis between miRNA expression levels and sputum cell counts 
revealed that expression of miR-629-3p, miR-223-3p, and miR-142-3p was positively 
associated with the percentage of sputum neutrophils and negatively correlated with 
the percentage of macrophages in the 2 independent cohorts (Fig 3, A-F, and see 
Table E8). In addition, expression among miR-629-3p, miR-223-3p, and miR-142-3p 
was highly correlated (Spearman rho > 0.65, P < 10-6; Fig 3, G-I). 
Multiple linear regression analysis demonstrated that miR-629-3p expression was 
significantly associated with neutrophil percentages, whereas expression of miR-223-
3p and miR-142-3p was significantly associated with neutrophil percentages and 
FEV1/FVC ratio (or FEV1), even after adjusting for age, BMI, atopy, sex, ICS use, and 
pack years (Table III and data not shown). 
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TABLE III. Multiple linear regression analysis to model which factors determine 
miRNA expression (validation cohort) 
miRNA ID Adjuste
d R2 
P value model Predictor 
variable 
β P value 
Multiple linear regression 
miR-629-3p 0.239 .011 Age 0.003 .986 
   BMI -0.165 .324 
   Atopy 0.146 .290 
   Sex -0.209 .144 
   FEV1/FVC ratio -0.255 .126 
   ICS (yes/no) 0.142 .372 
   Neutrophils (%) 0.494 .002 
   Pack years -0.197 .236 
miR-223-3p 0.361 .0001 Age -0.084 .518 
   BMI -0.050 .714 
   Atopy 0.002 .989 
   Sex -0.170 .154 
   FEV1/FVC ratio -0.329 .016 
   ICS (yes/no) 0.080 .540 
   Neutrophils (%) 0.575 <.001 
   Pack years -0.114 .399 
miR-142-3p 0.319 .0005 Age -0.014 .918 
   BMI 0.060 .669 
   Atopy 0.019 .869 
   Sex -0.292 .021 
   FEV1/FVC ratio -0.393 .006 
   ICS (yes/no) 0.017 .898 
   Neutrophils (%) 0.543 <.001 
   Pack years -0.299 .037 
Multiple linear regression (stepwise method) 
miR-629-3p 0.228 .0003 Neutrophils % 0.493 <.001 
miR-223-3p 0.382 4.1 × 10-7 Neutrophils (%) 0.492 <.001 
   FEV1/FVC ratio -0.296 .007 
miR-142-3p 0.286 .00003 Neutrophils (%) 0.413 .001 
   FEV1/FVC ratio -0.284 .016 
 
FIG 4. Origin of miR-629-3p, miR-223-3p, and miR-142-3p in sputum. A-C and G-l, In situ localization 
of miRNA expression (blue color) in bronchial biopsy specimens. Fig 4, A and B, miR-629-3p 
expression in patients with severe asthma. Fig 4, C, No staining for miR-629-3p in healthy control 
subjects. Fig 4, G-H, miR-223-3p expression in patients with severe asthma. Fig 4, /, Faint staining for 
miR-223-3p in healthy control subjects. Tissue was counterstained with nuclear fast red. D-F and J-L, 
Localization of neutrophil elastase-positive cells (red color, indicated by black arrows) in bronchial 
biopsy specimens in corresponding regions of consecutive sections of Fig 4, A-C and G-l, respectively. 
Tissue was counterstained with hematoxylin (blue). Black stars represents regions where miR-223-3p 
and neutrophil elastase are colocalized. M and N, Expression of miR-223-3p (Fig 4, M) and miR-142-
3p (Fig 4, N) in sorted cell subsets in sputum. Sputum cells (n = 2-5, depending on cell type) were 

















; see Fig E3 for the gating strategy. 
miRNA expression was normalized to snord95, snord96A, and snord68. Log10-based values are 
shown. 
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FIG 5. Bioinformatic workflow to discover the functional role of miR-629-3p, miR-223-3p, and miR-
142-3p in asthmatic patients. KEGG, Kyoto Encyclopedia of Genes and Genomes. 
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FIG 6. A and B, Spearman correlations between IL-1 β (in picograms per milliliter) and miR-223-3p 
(Fig 6, A) and IL-1β (in picograms per milliliter) and miR-142-3p (Fig 6, B) in sputum supernatants of 
the validation cohort. C and E-J, mRNA expression of genes relevant to asthma and/or direct miRNA 
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targets in HBECs transfected with mimics for miR-629-3p, miR-223-3p, and miR-142-3p or negative 
scrambled control (NegSCR; n = 4 per group). D, IL-8 protein levels in supernatants of HBECs 
transfected with mimics for miR-629-3p, miR-223-3p, and miR-142-3p (n = 4 per group). *P< .05, **P< 






Cellular origin of miR-629-3p, miR-223-3p, and miR-142-3p 
Using in situ hybridization on bronchial biopsy specimens of patients with severe 
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asthma, we demonstrated that miR-629-3p expression was confined to epithelial cells 
(Fig 4, A and B). Neutrophil elastase-positive cells were present just below epithelial 
miR-629-3p expression (Fig 4, D and E). The miR-223-3p expression was mainly 
localized just below the epithelium in the lamina propria (Fig 4, G and H, 
respectively). Neutrophil elastase-positive cells colocalized with miR-223-3p 
expression (Fig 4, G, H, J, and K) but were also detectable in regions with faint or no 
miR-223-3p expression. In bronchial biopsy specimens of control subjects, 
expression of miR-629-3p was undetectable, whereas very faint expression of miR-
223-3p was detectable (Fig 4, C and I, respectively). 
We sorted sputum cell subsets using flow cytometry19 to examine miRNA expression 
by using RT-PCR (Fig 4, M and N, and see Fig E3 in this article's Online Repository 
at www.jacionline.org for the gating strategy). Expression of miR-223-3p and miR-
142-3p was detectable in sputum macrophages, monocytes, and neutrophils and was 
highest in neutrophils (Fig 4, M and N). miR-629-3p was not detectable in these cell 
subsets (data not shown). 
 
In silico analysis into the functional role of miRNAs 
All experimentally validated targets of the 3 miRNAs were retrieved by using 
miRWalk 2.0 (129 genes) to elucidate the potential role of the identified miRNAs in 
asthmatic patients.20 Using gene expression data from bronchial epithelial cells 
(GSE63142),21 bronchoalveolar lavage macrophages (GSE7368),22 and 
bronchoalveolar lavage neutrophils (GSE2322),23 we identified 110 genes from the 
129 genes as being specifically expressed in these cell types (see Fig E4 in this 
article's Online Repository at www.jacionline.org). Within all Kyoto Encyclopedia of 
Genes and Genomes pathway24,25 gene sets, we selected those containing at least 1 
of the 110 potential target genes (see Fig E5 in this article's Online Repository at 
www.jacionline.org for full list and Fig 5). Several of the identified pathways are of 
interest to asthma and inflammation, such as mitogen-activated protein kinase 
(MAPK) signaling, nucleotide-binding oligomerization domain (NOD)-like receptor 
signaling, Toll-like receptor signaling, Janus kinase-signal transducer and activator of 
transcription signaling, and the TGF-β signaling pathways. 
 
Sputum cytokine levels are increased in patients with severe asthma and 
correlate with expression of miR-223-3p and miR-142-3p 
Because several of the validated targets of miR-223-3p, miR-142-3p, and miR-629-
3p are involved in inflammatory pathways (eg, NOD-like receptor, Toll-like receptor, 
and MAPK signaling), we determined protein levels of the proinflammatory mediators 
IL-1β, IL-6, and IL-8 in sputum supernatants. Patients with severe asthma showed 
significantly increased levels of IL-lβ and IL-8 in induced sputum compared with 
healthy subjects in the 2 cohorts, whereas levels tended to be intermediate in 
patients with mild-to-moderate asthma (see Fig E6, A-F, in this article's Online 
Repository at www.jacionline.org). IL-1β and IL-8 levels were negatively associated 
with FEV1 and FEV1/FVC ratio, yet this reached significance only in the screening 
cohort (see Table E9 in this article's Online Repository at www.jacionline.org). 
Importantly, IL-1β and IL-8 levels correlated significantly with sputum neutrophilia, 
and expression of miR-223-3p and miR142-3p correlated with IL-lβ levels (Fig 6, A 
and B, and see Table E9). Levels of the type 2 cytokine IL-5 increased in patients 
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with mild-to-moderate and those with severe asthma and in patients with eosinophilic 
asthma but did not correlate with any of the identified miRNAs (see Fig E6, G and H, 
and Table E9). 
 
Mimics of miR-629-3p, miR-223-3p, and miR-142-3p alter gene expression in 
HBECs 
The biological role of the identified miRNAs was investigated by transfecting primary 
HBECs with miRNA mimics. Expression of proinflammatory genes and direct or 
indirect miRNA targets related to asthma, wound repair, and inflammation (based on 
the literature26-30 and miRWalk 2.0) was investigated. Expression of IL-8 (mRNA and 
protein) and IL6 mRNA significantly increased after treatment with miR-629-3p mimic 
compared with the other groups (Fig 6, C-E). TGFBR1,26 vimentin (VIM),27 and 
adenomatous polyposis coli (APC)28 mRNA levels were significantly modulated after 
treatment with the different miRNA mimics (Fig 6, F-H). FBXW7 mRNA levels were 
downregulated by mimics of miR-223-3p and miR-629-3p and increased by miR-142-
3p mimic. PARP1 was downregulated by the miR-223-3p mimic (Fig 6,I and J). 
 
DISCUSSION 
In this study we identified miR-629-3p, miR-223-3p, and miR-142-3p expression as 
upregulated in sputum supernatants of patients with severe neutrophilic asthma. 
Linear regression analysis demonstrated that expression of the 3 miRNAs was 
associated with sputum neutrophilia. Moreover, miR-223-3p and miR-142-3p 
expression was significantly associated with airway obstruction (FEV1/FVC ratio). We 
demonstrated that miR-629-3p is expressed in the bronchial epithelium, whereas 
miR-223-3p and miR-142-3p are expressed in neutrophils, monocytes, and 
macrophages. In silico analysis and functional experiments on HBECs transfected 
with miRNA mimics indicate that the identified miRNAs are influencing pathways 
related to inflammation and wound response. Finally, sputum supernatants of 
patients with severe asthma contained increased IL-1β and IL-8 levels, which were 
positively associated with sputum neutrophilia. 
To our knowledge, this is the first report describing a link between miR-629-3p, miR-
223-3p, and miR-142-3p expression in sputum and in patients with (severe) 
neutrophilic asthma. Induced sputum, which enables monitoring of genetic, 
biochemical, molecular, and cellular markers in the proximal airways,15,31 has been 
used to identify inflammatory phenotypes in asthma.32 Treatment directed toward 
normalization of sputum eosinophilia reduces asthma exacerbations,33 indicating that 
findings from induced sputum can have therapeutic potential. 
We showed (1) increased miR-629-3p expression in sputum supernatants of patients 
with severe neutrophilic asthma, (2) positive correlation between miR-629-3p 
expression and percentage of sputum neutrophils, (3) miR-629-3p expression in the 
bronchial epithelium of patients with severe asthma, and (4) that a miR-629-3p mimic 
induces IL-8 and IL-6 expression in HBECs. These findings suggest that miR-629-3p 
influences the pathogenesis of neutrophilic asthma by inducing epithelial expression 
of the neutrophil chemoattractant IL-8. In patients with liver inflammation, IL-6/IL-6 
receptor/signal transducer and activator of transcription 3 signaling promotes miR-
629 expression through a complex positive feedback loop mechanism.34 It is possible 
that IL-6 released during inflammation promotes epithelial miR-629-3p expression in 
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patients with severe asthma, further perpetuating IL-6 expression and signaling. 
Because miRNAs are known as repressors of gene expression, the proinflammatory 
effects likely occur through an indirect mechanism. One possible candidate is 
FBXW7, a validated miRWalk 2.0 target of miR-223-3p, expression which was also 
downregulated in HBECs treated with the miR-629-3p mimic. FBXW7 has been 
identified as a suppressor of Toll-like receptor 4-mediated inflammatory gene 
expression by downregulating C/EBPδ.29 Further research is needed to unravel the 
method of action of miR-629-3p. Notably PARP1, a miR-223-3p target and 
coactivator of the nuclear factor kappa-light chain enhancer of activated B cells that 
facilitates IL-8 expression,30 was downregulated by the miR-223-3p mimic in HBECs. 
We demonstrated increased miR-223-3p expression in patients with severe and 
those with neutrophilic asthma. Previous studies with airway biopsy specimens and 
bronchial brushings revealed no differential expression4 or upregulated miR-223-3p 
expression5 in patients with mild asthma; however, no association with inflammatory 
cell profiles was made. Upregulated miR-223-3p expression was demonstrated both 
in patients with cystic fibrosis35 and those with active tuberculosis36 and was 
suggested to play an active role in disease pathogenesis. In smokers with chronic 
pulmonary disease, pulmonary miR-223-3p expression was increased compared with 
that in smokers without airflow obstruction,37 whereas bronchial airway epithelium 
from smokers showed decreased miR-223 expression compared with nonsmokers. 
When ex-smokers were excluded from our cohort to avoid smoking effects, 
expression of the 3 miRNAs remained increased in patients with neutrophilic asthma 
(data not shown). Notably, in patients with different lung diseases characterized by 
neutrophilic inflammation and airway obstruction, increased miR-223-3p expression 
and increased IL-1β and IL-8 levels were reported.35,39-41 
Because in silico analysis on validated miRNA targets expressed in bronchial 
epithelial cells, neutrophils, or macrophages suggested that the identified miRNAs 
are implicated in inflammatory pathways (Toll-like receptor, NOD-like receptor, and 
MAPK signaling, yielding in IL-1β, IL-6, and IL-8), we measured levels of 
proinflammatory cytokines in sputum supernatants. IL-1β and IL-8 levels were 
significantly increased in patients with severe asthma and correlated with neutrophil 
counts in sputum. These data are similar to recent findings of Simpson et al41 and 
Baines et al,42 who elegantly demonstrated increased IL-1β and IL-8 levels and 
NLRP3 expression in patients with neutrophilic asthma. 
We demonstrated miR-223-3p and miR-142-3p expression in sputum neutrophils, 
monocytes, and macrophages, which corresponds with previous studies in human 
alveolar macrophages4 and blood neutrophils and monocytes.43 How miR-223-3p is 
implicated in inflammatory processes in neutrophilic asthma requires further 
investigation because miR-223-3p expression can downregulate IL-1β synthesis 
through NLRP3 repression on the one hand44,45 but is also induced by IL-1β on the 
other hand.35 
Notably, miR-223-3p and miR-142-3p expression in sputum supernatants was 
strongly correlated (Spearman Rho = 0.889, P < 10-6). This corresponds with 
literature because miR-223-3p can upregulate miR-142-3p expression through a 
miR-223-3p-CEBP-β-LM02-miR-142-3p regulatory pathway46 
In accordance with the literature, the miR-142-3p mimic reduced TGFBR1 expression 
in HBECs.26 The canonical TGF-β-Smad3 pathway is activated in asthmatic patients 
and is associated with increased VIM expression during epithelial-mesenchymal 
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transition.47 The miR-223-3p mimic induced TGFBR1 and VIM expression and 
reduced FBXW7 expression in HBECs. In the literature increased expression of miR-
223-3p and VIM and reduced FBXW7 expression was described in epithelial-
mesenchymal transition in patients with pancreatic cancer.27 However, the effects of 
the miRNA mimics on different genes suggest a complex regulatory network. In 
addition, miR-142-3p mimic also inhibited expression of APC, an inhibitor of WNT 
signaling.28 We showed no epithelial miR-223-3p and miR-142-3p expression on 
tissue sections, yet a transfer of miRNAs (eg, miR-223-3p) from inflammatory cells to 
the epithelium is possible.48 
Our findings for miR-629-3p, miR-223-3p, and miR-142-3p combined with the 
literature suggest that an imbalanced expression could determine the progression to 
uncontrolled inflammation and wound repair pathways in patients with severe 
asthma. 
A limitation of our study is that the validation cohort included a significant number of 
patients with mild neutrophilic asthma (n = 11), a rather rare phenotype of mild 
asthma. Although this patient distribution does not reflect the distribution found in 
clinical practice, this enabled us to investigate whether miRNA expression was 
associated with disease severity, neutrophilic inflammation, or both. Remarkably, no 
published miRNAs related to eosinophilia or type 2 responses9 were identified in the 
screening cohort. This is possibly because in sputum supernatants only a limited 
amount of miRNAs could be quantified. In addition, most published studies have 
analyzed more homogenous patient cohorts, with a typical mild-to-moderate TH2-type 
asthmatic phenotype. Finally, the dose of ICSs could have driven differential miRNA 
expression in patients with mild versus severe asthma. However, we found no 
correlation between ICS dose and miRNA expression (data not shown). 
Despite these limitations, the strong associations between miRNA expression, 
inflammatory parameters, lung function, and cytokine levels in patients with severe 
neutrophilic asthma and the functional experiment in HBECs indicate that these 
miRNAs could contribute to the pathogenesis of neutrophilic asthma. Further 
research into the interactions between miR-629-3p, miR-223-3p, and miR-142-3p 
could provide potential therapeutic targets for lung diseases characterized by 
neutrophilia and airway obstruction. 
In conclusion, we have identified expression of miR-629-3p, miR-223-3p, and miR-
142-3p as increased in patients with (severe) neutrophilic asthma and suggest that 
these miRNAs actively contribute to the disease pathogenesis by modulating 






•  In 2 independent cohorts of asthmatic patients, expression of miR-629-3p, 
miR-223-3p, and miR-142-3p in induced sputum is increased in patients with 
severe asthma and positively associated with neutrophilic airway inflammation. 
•  A miR-629-3p mimic induces upregulation of IL-8 in bronchial epithelial cells, 
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providing a mechanistic link between increased miR-629-3p expression and 
airway neutrophilia in patients with severe asthma. 
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